IP Library › Granted Patent US 9,687,529
Granted Patent B2
US 9,687,529 · App. 14/115,797 · Granted Jun 27, 2017

Method of controlling coagulation

Inventors: Bruce A Sullenger (Durham, NC); Jens Lohrmann (Durham, NC); James Frederiksen (Durham, NC); Kristin Bompiani (Durham, NC)
Assignee: Duke University
A61K38/36A61K31/702A61K31/7088A61K31/713A61K38/58A61K45/06C12N15/115C12N2310/113C12N2310/16C12N2310/51C12N2320/31C12N2320/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,687,529
App. No.
14/115,797
Granted
Jun 27, 2017
Kind
B2
Abstract

The present invention relates, in general, to methods of controlling coagulation, and in particular, to methods of effecting neutralizable rapid onset anticoagulation, and to compounds and compositions suitable for use in such methods.

Claims (17)

1. A composition comprising at least two agents that directly inhibit more than one step in a coagulation pathway and a carrier, wherein one of the agents is capable of inhibiting Factor X or Factor Xa and the other agent is capable of inhibiting prothrombin or thrombin, wherein the agents are aptamers and the aptamers are 11F7T (SEQ ID NO:2) and R9D-14T (SEQ ID NO: 3 or 13).

2. A composition comprising two agents that each directly inhibit a different step in a coagulation pathway and a carrier, wherein the agents are aptamers and the aptamers are linked to form a single nucleic acid molecule, and wherein the aptamers are 11F7T (SEQ ID NO: 2) and R9D-14T (SEQ ID NO: 3 or 13).

3. The composition of claim 2 , wherein the aptamers comprise a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-24.

4. A method of controlling coagulation comprising administering to a subject in need thereof the composition of claim 2 in an amount sufficient to control coagulation.

5. The method according to claim 4 , wherein said subject is a surgery patient or the subject suffers from stroke or deep vein thrombosis.

6. The method according to claim 4 , wherein said subject is undergoing cardiopulmonary bypass surgery or percutaneous coronary intervention.

7. The method of claim 4 , wherein the aptamers comprise a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-24.

8. The composition of claim 1 , wherein at least one of the aptamers may be neutralized by an aptamer-specific antidote oligonucleotide or a nucleic acid binding polymer.

9. The composition of claim 8 , wherein the nucleic acid binding polymer is protamine or a cyclodextrin-containing polycation (CDP).

10. The composition of claim 1 , wherein the aptamers are linked to form a single nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-24.

11. A method of controlling coagulation comprising administering to a subject in need thereof the composition of claim 1 in an amount sufficient to control coagulation.

12. The method of claim 11 , wherein said subject is a surgery patient or suffers from stroke or deep vein thrombosis.

13. The method of claim 11 , wherein the aptamers are linked to form a single nucleic acid molecule comprising a nucleic acid sequence selected from at least one of SEQ ID NOs: 19-24.

14. A composition comprising two agents that each directly inhibit a different step in a coagulation pathway and a carrier, wherein the agents are aptamers and the aptamers are linked to form a single nucleic acid molecule, and wherein the aptamers comprise a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 15-24.

15. A method of controlling coagulation comprising administering to a subject in need thereof the composition of claim 14 in an amount sufficient to control coagulation.

16. The method of claim 15 , wherein said subject is a surgery patient or suffers from stroke or deep vein thrombosis.

17. The method according to claim 16 , wherein said subject is undergoing cardiopulmonary bypass surgery or percutaneous coronary intervention.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2014
From: SULLENGER, BRUCE A.; FREDERIKSEN, JAMES; LOHRMANN, JENS; BOMPIANI, KRISTIN
To: DUKE UNIVERSITY
Reel/Frame 033172/0596 →
Continuity (2)
Provisional Application 61457642 · May 5, 2011
Related Publication 20140275226A1 · Sep 18, 2014